Evaluation of Implementation of the Phoenix PrEP (Pre-Exposure Prophylaxis) Access Project for Youth Aged 13-24
1 other identifier
observational
42
1 country
1
Brief Summary
This study will evaluate the implementation of a PrEP program for youth aged 13-24 in Phoenix, AZ. Numbers of youth who initiate PrEP, how long they continue with PrEP, and the barriers for youth who are trying to initiate and continue taking PrEP will be examined.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 27, 2018
CompletedStudy Start
First participant enrolled
June 1, 2018
CompletedFirst Posted
Study publicly available on registry
August 20, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedMarch 31, 2023
March 1, 2023
4.6 years
February 27, 2018
March 30, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
PrEP Uptake
Uptake of PrEP offered to youth presenting for PrEP ages 13-24
3 years
Eligibility Criteria
Youth aged 13 through 24 in the Phoenix area who are high risk for HIV infections because of unsafe sex practices and or IV drug use and have been offered PrEP as part of their standard medical care.
You may qualify if:
- sexually active youth aged 13 through 24,
- at risk for contracting HIV,
- Negative for HIV as indicated by Negative Elisa and Western Blot (WB) or Negative 4th Generation test,
- weight greater than 35kg,
- offered PrEP to reduce the risk of contracting HIV.
You may not qualify if:
- Unknown or Positive HIV status,
- Renal Impairment as indicated by elevated BUN or Creatinine, abnormal urinalysis,
- Active infection with Hepatitis B Virus,
- Taking other medications containing Emtricitabine, Tenofovir or tenofovir alafenamide(TAF) such as Atripla, Complera, Emtriva, Genvoya, Odefsey, Stribild, and Viread taking drugs containing lamivudine,
- taking Hepsera,
- clinical symptoms consistent with acute viral infection within the past month.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Phoenix Children's Hospital, Bill Holt Clinic
Phoenix, Arizona, 85044, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Janice Piatt, MD
Phoenix Children's Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 27, 2018
First Posted
August 20, 2018
Study Start
June 1, 2018
Primary Completion
December 31, 2022
Study Completion
December 31, 2022
Last Updated
March 31, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share